John C. Reed - May 1, 2024 Form 4/A - Amendment Insider Report for JOHNSON & JOHNSON (JNJ)

Role: EVP, Innovative Medicine, R&D
Signature: /s/ Laura McFalls, as attorney-in-fact for John C. Reed
Stock symbol: JNJ
Transactions as of: May 1, 2024
Transactions value $: -$1,588,177
Form type: 4/A - Amendment
Date filed: 10/31/2024, 05:57 PM
Date Of Original Report: May 3, 2024
Previous filing: Feb 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JNJ	Common Stock	Options Exercise	$0	+25.3K	+8253.27%	$0.00	25.6K	May 1, 2024	Direct	F1
transaction	JNJ	Common Stock	Tax liability	-$1.59M	-11K	-42.97%	$144.59	14.6K	May 1, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JNJ	Restricted Share Units	Options Exercise	$0	-25.3K	-33.33%	$0.00	50.5K	May 1, 2024	Common Stock	25.3K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting.
F2	Shares withheld for payment of taxes upon vesting of Restricted Share Units.

Remarks:

This Form 4 is being amended to correct Table I and Table II above, as follows: (i) to correct and restate the total number of shares transacted; and (ii) to correct and restate the number of securities beneficially owned following the reported transaction as of May 1, 2024.